Molecular Biology Reports

, Volume 39, Issue 1, pp 771–774 | Cite as

Type 17 T-helper cells might be a promising therapeutic target for osteoporosis

  • Feng-Lai Yuan
  • Xia Li
  • Wei-Guo Lu
  • Yi-Qing Zhao
  • Cheng-Wan Li
  • Jian-Ping Li
  • Jun-Ming Sun
  • Rui-Sheng Xu
Article

Abstract

Osteoporosis, a disease characterized by low bone mass and deterioration of bone tissue, is a pressing public health problem. Recent studies have suggested a possible role of T-helper (Th) cells in the pathogenesis of bone loss which occurs in systemic inflammatory diseases. However, there are contradictions in the published literature regarding the functional role of Th1/Th2 cells in the regulation of the differentiation of osteoclasts. These paradoxes have now been clarified by the recent discovery of Th17 cells, a novel subset of Th cells that selectively secrete several proinflammatory cytokines, mainly IL-17. It has been confirmed that Th17 cells have stimulatory effects on osteoclastogenesis and accelerate bone loss in animal models with inflammatory disorders. Targeting Th17 cells or IL-17 may inhibit the bone resorption with RA. Thus, we are led to suppose that Th17 cells might be promising therapeutic targets in osteoporosis.

Keywords

Type 17 T-helper cells Cytokines Osteoclasts Osteoporosis 

References

  1. 1.
    Canalis E (2010) Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab 95:1496–1504PubMedCrossRefGoogle Scholar
  2. 2.
    Takayanagi H (2010) New immune connections in osteoclast formation. Ann NY Acad Sci 1192:117–123PubMedCrossRefGoogle Scholar
  3. 3.
    Yuan FL, Li X, Lu WG et al (2010) Regulatory T cells as a potent target for controlling bone loss. Biochem Biophys Res Commun 402:173–176PubMedCrossRefGoogle Scholar
  4. 4.
    Yuan FL, Hu W, Lu WG et al (2011) Targeting interleukin-21 in rheumatoid arthritis. Mol Biol Rep 38:1717–1721PubMedCrossRefGoogle Scholar
  5. 5.
    Takayanagi H (2009) Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 5:667–676PubMedCrossRefGoogle Scholar
  6. 6.
    Pan HF, Ye DQ, Li XP (2008) Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat Clin Pract Rheumatol 4:352–353PubMedGoogle Scholar
  7. 7.
    Rifas L, Weitzmann MN (2009) A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum 60:3324–3335PubMedCrossRefGoogle Scholar
  8. 8.
    Yuan FL, Li X, Lu WG et al (2010) The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis. Mol Biol Rep 37:3561–3566PubMedCrossRefGoogle Scholar
  9. 9.
    McLean RR (2009) Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep 7:134–139PubMedCrossRefGoogle Scholar
  10. 10.
    McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429–442PubMedCrossRefGoogle Scholar
  11. 11.
    Redlich K, Hayer S, Ricci R et al (2002) Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110:1419–1427PubMedGoogle Scholar
  12. 12.
    Sato K, Suematsu A, Okamoto K et al (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673–2682PubMedCrossRefGoogle Scholar
  13. 13.
    Kramer JM, Gaffen SL (2007) Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy. J Periodontol 78:1083–1093PubMedCrossRefGoogle Scholar
  14. 14.
    Quinn JM, Sims NA, Saleh H et al (2008) IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J Immunol 181:5720–5729PubMedGoogle Scholar
  15. 15.
    Annunziato F, Cosmi L, Liotta F et al (2009) Type 17 T-helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 5:325–331PubMedCrossRefGoogle Scholar
  16. 16.
    Kamiya S, Nakamura C, Fukawa T et al (2007) Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J Bone Miner Metab 25:277–285PubMedCrossRefGoogle Scholar
  17. 17.
    Yago T, Nanke Y, Ichikawa N et al (2009) IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem 108:947–955PubMedCrossRefGoogle Scholar
  18. 18.
    Li X, Yuan FL, Lu WG et al (2010) The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem Biophys Res Commun 397:131–135PubMedCrossRefGoogle Scholar
  19. 19.
    Lubberts E, van den Bersselaar L, Oppers-Walgreen B et al (2003) IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 170:2655–2662PubMedGoogle Scholar
  20. 20.
    Bush KA, Farmer KM, Walker JS et al (2002) Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 46:802–805PubMedCrossRefGoogle Scholar
  21. 21.
    Chabaud M, Miossec P (2001) The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 44:1293–1303PubMedCrossRefGoogle Scholar
  22. 22.
    Korn T, Oukka M, Kuchroo V et al (2007) Th17 cells: effector T cells with inflammatory properties. Semin Immunol 19:362–371PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Feng-Lai Yuan
    • 1
  • Xia Li
    • 2
  • Wei-Guo Lu
    • 2
  • Yi-Qing Zhao
    • 2
  • Cheng-Wan Li
    • 2
  • Jian-Ping Li
    • 2
  • Jun-Ming Sun
    • 2
  • Rui-Sheng Xu
    • 3
  1. 1.Central Laboratory, The Third Hospital Affiliated to Nantong UniversityWuxiChina
  2. 2.The Third Hospital Affiliated to Nantong UniversityWuxiChina
  3. 3.Department of Orthopaedic Surgery, The Third Hospital Affiliated to Nantong UniversityWuxiChina

Personalised recommendations